139 related articles for article (PubMed ID: 27732334)
1. Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
Zhang Y; Sui F; Ma J; Ren X; Guan H; Yang Q; Shi J; Ji M; Shi B; Sun Y; Hou P
J Clin Endocrinol Metab; 2017 Feb; 102(2):613-624. PubMed ID: 27732334
[TBL] [Abstract][Full Text] [Related]
2. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.
Lv Y; Sui F; Ma J; Ren X; Yang Q; Zhang Y; Guan H; Shi B; Hou P; Ji M
Oncotarget; 2016 Sep; 7(36):57978-57990. PubMed ID: 27517321
[TBL] [Abstract][Full Text] [Related]
4. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
[TBL] [Abstract][Full Text] [Related]
5. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
[TBL] [Abstract][Full Text] [Related]
6. NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas.
Górka B; Skubis-Zegadło J; Mikula M; Bardadin K; Paliczka E; Czarnocka B
Br J Cancer; 2007 Aug; 97(4):531-8. PubMed ID: 17667921
[TBL] [Abstract][Full Text] [Related]
7. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
8. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
9. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
10. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
11. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Li H; Tian Z; Qu Y; Yang Q; Guan H; Shi B; Ji M; Hou P
Oncogene; 2019 Jan; 38(3):345-359. PubMed ID: 30093629
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.
Zhang H; Teng X; Liu Z; Zhang L; Liu Z
J Exp Clin Cancer Res; 2015 Feb; 34(1):16. PubMed ID: 25887589
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
[TBL] [Abstract][Full Text] [Related]
14. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.
Zhou Q; Chen J; Feng J; Xu Y; Zheng W; Wang J
Mol Cell Biochem; 2017 Nov; 435(1-2):87-95. PubMed ID: 28551845
[TBL] [Abstract][Full Text] [Related]
15. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
16. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway.
Wang Y; Lin X; Fu X; Yan W; Lin F; Kuang P; Luo Y; Lin E; Hong X; Wu G
Oncol Rep; 2018 Aug; 40(2):859-866. PubMed ID: 29917164
[TBL] [Abstract][Full Text] [Related]
18. KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.
Lee J; Seol MY; Jeong S; Kwon HJ; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Lee EJ; Chung WY; Jo YS
J Mol Endocrinol; 2015 Apr; 54(2):115-24. PubMed ID: 25608512
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.
Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
